Skip to content
mapperlab
← Dashboard
Stock

CRMD

CORMEDIX INC.
Latest close $7.913 of 27 marquee funds currently hold3 CUSIPs mapped
Current holders
3
27 funds tracked
Ever held
8
Current + past
New this quarter
0
Exited this quarter
3

Marquee-fund ownership over time

Aug 14, 2013Aug 14, 2024Aug 13, 2025May 15, 2026
Now
3

This quarter's activity

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Citadel Advisors$4.92$7.91+61%
Two Sigma Investments$4.92$7.91+61%
AQR Capital Management re-entered$4.92$7.91+61%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
D.E. Shaw 2× in & out→ $7.55+5%
Millennium Management→ $7.55+53%
Point72 Asset Management→ $11-11%
Renaissance Technologies 3× in & out→ $11-7%
Elliott Management 3× in & out+0%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at CorMedix Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
18
Filings · last 90d
27
Total on file
430
Recent SEC buffer
Most recent
Feb 6, 2026

30d / 90d windows measured from Feb 6, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 430 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · CORMEDIX INC.

Annual figures sourced directly from CORMEDIX INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$311.71M
FY2025+500%+ YoY
Net income
$163.06M
FY2025+500%+ YoY
EPS (diluted)
$2.04
FY2025+500%+ YoY
Free cash flow(?)
$172.79M
FY2025+441% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for CorMedix Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
D.E. ShawQ1 2026Q2 2026$7.21$7.55+5%
Point72 Asset ManagementQ3 2025Q4 2025$13$11-11%
Renaissance TechnologiesQ3 2025Q4 2025$12$11-7%
AQR Capital ManagementQ1 2025open$10$7.91-25%
Renaissance TechnologiesQ1 2025Q2 2025$10$12+11%
Citadel AdvisorsQ3 2024open$4.92$7.91+61%
Two Sigma InvestmentsQ3 2024open$4.92$7.91+61%
D.E. ShawQ3 2024Q4 2025$4.92$11+128%
AQR Capital ManagementQ3 2024Q4 2024$4.92$11+124%
Millennium ManagementQ3 2024Q2 2026$4.92$7.55+53%
Renaissance TechnologiesQ3 2024Q4 2024$3.82$11+197%
Elliott ManagementQ2 2019Q2 2020$0.00+0%
Elliott ManagementQ3 2013Q3 2015$0.00+0%
Elliott ManagementQ3 2013Q2 2019$0.00+0%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.